ImmunityBio, Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.www.immunitybio.com
2
MENTIONS
2
EPISODES
2
PODCASTS
Search complete. 2 mentions across 2 episodes found for "ImmunityBio, Inc.".
Sep 15, 2026
Megan BashamGUEST
Um, I have been very proactive in seeking out some, uh, additional therapies.
Megan BashamGUEST
I did the traditional chemo, radiation, surgery, uh, but I also sought out some treatment at Immunity Bio in California which, if you're not familiar, you probably are, Alex.
Megan BashamGUEST
Have you heard of Patrick Soon-Shiong?
Alex ClarkHOST
Um, actually I think I have, yes.
Tony LyonsHOST
Next up, we have Dr. Patrick Soon-Chiang, and he's a physician, a scientist, a biotech person known for pioneering cancer research and cancer therapies.
Tony LyonsHOST
He founded Immunity Bio in 2014 to develop next generation therapies that activate the immune system to fight cancer and, you know, really anything else.
Tony LyonsHOST
So welcome, Patrick.
Tony LyonsHOST
Great to have you on again.